ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 31.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,457 shares of the specialty pharmaceutical company’s stock after buying an additional 1,527 shares during the period. Envestnet Asset Management Inc.’s holdings in ANI Pharmaceuticals were worth $432,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock worth $10,565,000 after buying an additional 64,021 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of ANI Pharmaceuticals by 53.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock valued at $599,000 after acquiring an additional 3,112 shares in the last quarter. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after purchasing an additional 881 shares during the period. Stifel Financial Corp grew its position in ANI Pharmaceuticals by 20.4% during the 4th quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock worth $466,000 after purchasing an additional 1,425 shares in the last quarter. Finally, Northern Trust Corp grew its position in ANI Pharmaceuticals by 9.0% during the 4th quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company’s stock worth $11,296,000 after purchasing an additional 16,820 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $64.88, for a total value of $25,952.00. Following the sale, the vice president directly owned 78,945 shares in the company, valued at $5,121,951.60. This trade represents a 0.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares in the company, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,681 shares of company stock valued at $345,222 over the last three months. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright began coverage on ANI Pharmaceuticals in a report on Thursday, July 10th. They set a “buy” rating and a $84.00 price target on the stock. Truist Financial raised their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research report on Monday, April 21st. Wall Street Zen downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Finally, Guggenheim reissued a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.88.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $69.09 on Thursday. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00. The company’s 50-day moving average is $64.53 and its two-hundred day moving average is $63.59. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. The company has a market cap of $1.50 billion, a PE ratio of -54.40 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to analysts’ expectations of $179.75 million. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The business’s revenue for the quarter was up 43.4% on a year-over-year basis. During the same period last year, the firm earned $0.82 earnings per share. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.